What is HC Wainwright’s Estimate for Ocugen FY2026 Earnings?

Ocugen, Inc. (NASDAQ:OCGN) – Stock analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Ocugen in a report issued on Wednesday, November 4th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.22) per share for the year, up from their previous estimate of ($0.27). The consensus estimate for Ocugen’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Ocugen’s Q4 2026 earnings at ($0.08) EPS.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen cut Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Weiss Ratings upgraded shares of Ocugen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.50.

Ocugen Trading Down 6.6%

OCGN opened at $0.82 on Friday. Ocugen has a 52 week low of $0.69 and a 52 week high of $2.73. The business’s 50 day moving average is $0.99 and its two-hundred day moving average is $1.41. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 4.17.

Ocugen (NASDAQ:OCGN) last announced its earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $0.89 million.

Hedge Funds Weigh In On Ocugen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Ocugen in the 2nd quarter valued at about $41,314,000. Bank of America Corp DE purchased a new stake in Ocugen during the 2nd quarter valued at approximately $3,046,000. Hennion & Walsh Asset Management Inc. raised its stake in Ocugen by 121.7% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 2,830,397 shares of the company’s stock valued at $4,331,000 after acquiring an additional 1,553,672 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Ocugen during the 2nd quarter worth approximately $1,238,000. Finally, Headlands Technologies LLC lifted its position in Ocugen by 527.1% during the 2nd quarter. Headlands Technologies LLC now owns 511,575 shares of the company’s stock worth $783,000 after acquiring an additional 429,997 shares during the period. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Insider Buying and Selling

In other news, CEO Shankar Musunuri sold 468,727 shares of the company’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $0.95, for a total value of $445,290.65. Following the completion of the sale, the chief executive officer directly owned 4,018,470 shares of the company’s stock, valued at approximately $3,817,546.50. This represents a 10.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,051,982 shares of company stock valued at $1,088,801 in the last quarter. Insiders own 3.95% of the company’s stock.

Key Headlines Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Ocugen’s Q3 revenue exceeded analyst expectations, while its quarterly loss was generally reported as in line with estimates. Coverage linked the results to a sharp rise in the shares. Ocugen’s Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
• Positive Sentiment: Management said all three late-stage modifier gene therapy programs have reached Phase 3, with key data readouts expected in 2027. The company is targeting three biologics license application submissions by 2028—important potential milestones for its pipeline. Ocugen Q3 2026 Earnings Call Highlights
• Positive Sentiment: Ocugen reported $84.6 million in cash and highlighted new licensing agreements, including a Middle East deal. Cash provides resources to advance its clinical programs, though future development and regulatory work will require continued funding. Ocugen Q3 2026 Earnings Call Transcript
• Neutral Sentiment: The company remains loss-making. The reported quarterly loss was in line with estimates, so it was not an obvious negative surprise, but Ocugen’s investment case continues to depend on clinical progress and eventual commercialization. Ocugen Reports Q3 Loss, Tops Revenue Estimates

About Ocugen

Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and vaccines for infectious diseases. The company’s programs are designed to address serious conditions with limited treatment options, including inherited retinal diseases and diseases affecting the central retina.

Ocugen’s pipeline includes modifier gene therapy candidates intended to treat multiple retinal disorders with a single therapeutic approach. Its lead programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease.